Cargando…
The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer
BACKGROUND: The lymphovascular space invasion (LVSI) is suggested as a prognostic factor for endometrial cancer in many studies, but it has not yet been employed in FIGO staging system. The present study was aimed to evaluate the impact of LVSI on survival in patients with early stage endometrioid e...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012545/ https://www.ncbi.nlm.nih.gov/pubmed/36915143 http://dx.doi.org/10.1186/s40001-023-01084-9 |
_version_ | 1784906624936181760 |
---|---|
author | Yarandi, Fariba Shirali, Elham Akhavan, Setare Nili, Fatemeh Ramhormozian, Sara |
author_facet | Yarandi, Fariba Shirali, Elham Akhavan, Setare Nili, Fatemeh Ramhormozian, Sara |
author_sort | Yarandi, Fariba |
collection | PubMed |
description | BACKGROUND: The lymphovascular space invasion (LVSI) is suggested as a prognostic factor for endometrial cancer in many studies, but it has not yet been employed in FIGO staging system. The present study was aimed to evaluate the impact of LVSI on survival in patients with early stage endometrioid endometrial cancer. METHODS: This retrospective cohort was conducted on early stage endometrial cancer patients who underwent surgical staging [total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH/BSO)] and omental biopsy at Referral Teaching Hospitals of Tehran from 2005 to 2021. Patient’s age, menopause status, tumor grade, tumor size, depth of myometrial invasion, LVSI and lower segment involvement were recorded. Data were analyzed with SPSS 22. RESULTS: 415 patients with stage I and grade 1–2, endometrioid endometrial cancer were analyzed. 100 patients (24.1%) were LVSI-positive. 3-year and 5-year survival rates were 97.1% and 88.9%, respectively. Recurrence occurred in 53 patients (12.8%). 3-year overall survival rates in LVSI-negative and LVSI-positive were 98.7% and 92%. These rates for 5-year survival were 92.1% and 79%, respectively. Recurrence rates in LVSI-negative were 8.9% while it was 25% in LVSI-positive cases. Multivariate analysis showed that LVSI has significant correlation with 3-year and 5-year overall survival rates. CONCLUSIONS: LVSI in early stage endometrial cancer significantly and independently influences 3-year and 5-year survival rates and acts as a strong prognostic factor in these patients. LVSI should be implemented in endometrial cancer staging systems due to its significant correlation with cancer recurrence rates and 5-year survival rates. |
format | Online Article Text |
id | pubmed-10012545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100125452023-03-15 The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer Yarandi, Fariba Shirali, Elham Akhavan, Setare Nili, Fatemeh Ramhormozian, Sara Eur J Med Res Research BACKGROUND: The lymphovascular space invasion (LVSI) is suggested as a prognostic factor for endometrial cancer in many studies, but it has not yet been employed in FIGO staging system. The present study was aimed to evaluate the impact of LVSI on survival in patients with early stage endometrioid endometrial cancer. METHODS: This retrospective cohort was conducted on early stage endometrial cancer patients who underwent surgical staging [total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH/BSO)] and omental biopsy at Referral Teaching Hospitals of Tehran from 2005 to 2021. Patient’s age, menopause status, tumor grade, tumor size, depth of myometrial invasion, LVSI and lower segment involvement were recorded. Data were analyzed with SPSS 22. RESULTS: 415 patients with stage I and grade 1–2, endometrioid endometrial cancer were analyzed. 100 patients (24.1%) were LVSI-positive. 3-year and 5-year survival rates were 97.1% and 88.9%, respectively. Recurrence occurred in 53 patients (12.8%). 3-year overall survival rates in LVSI-negative and LVSI-positive were 98.7% and 92%. These rates for 5-year survival were 92.1% and 79%, respectively. Recurrence rates in LVSI-negative were 8.9% while it was 25% in LVSI-positive cases. Multivariate analysis showed that LVSI has significant correlation with 3-year and 5-year overall survival rates. CONCLUSIONS: LVSI in early stage endometrial cancer significantly and independently influences 3-year and 5-year survival rates and acts as a strong prognostic factor in these patients. LVSI should be implemented in endometrial cancer staging systems due to its significant correlation with cancer recurrence rates and 5-year survival rates. BioMed Central 2023-03-13 /pmc/articles/PMC10012545/ /pubmed/36915143 http://dx.doi.org/10.1186/s40001-023-01084-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yarandi, Fariba Shirali, Elham Akhavan, Setare Nili, Fatemeh Ramhormozian, Sara The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer |
title | The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer |
title_full | The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer |
title_fullStr | The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer |
title_full_unstemmed | The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer |
title_short | The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer |
title_sort | impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012545/ https://www.ncbi.nlm.nih.gov/pubmed/36915143 http://dx.doi.org/10.1186/s40001-023-01084-9 |
work_keys_str_mv | AT yarandifariba theimpactoflymphovascularspaceinvasiononsurvivalinearlystagelowgradeendometrioidendometrialcancer AT shiralielham theimpactoflymphovascularspaceinvasiononsurvivalinearlystagelowgradeendometrioidendometrialcancer AT akhavansetare theimpactoflymphovascularspaceinvasiononsurvivalinearlystagelowgradeendometrioidendometrialcancer AT nilifatemeh theimpactoflymphovascularspaceinvasiononsurvivalinearlystagelowgradeendometrioidendometrialcancer AT ramhormoziansara theimpactoflymphovascularspaceinvasiononsurvivalinearlystagelowgradeendometrioidendometrialcancer AT yarandifariba impactoflymphovascularspaceinvasiononsurvivalinearlystagelowgradeendometrioidendometrialcancer AT shiralielham impactoflymphovascularspaceinvasiononsurvivalinearlystagelowgradeendometrioidendometrialcancer AT akhavansetare impactoflymphovascularspaceinvasiononsurvivalinearlystagelowgradeendometrioidendometrialcancer AT nilifatemeh impactoflymphovascularspaceinvasiononsurvivalinearlystagelowgradeendometrioidendometrialcancer AT ramhormoziansara impactoflymphovascularspaceinvasiononsurvivalinearlystagelowgradeendometrioidendometrialcancer |